Representative experience
Successfully defending leading research institutions in an FCA investigation involving multiple federal agencies and over US$1 billion of federal funding.
Defending a medical device company in an FCA qui tam case in which a manager sought damages for alleged kickbacks to physicians.
Advising a radiation therapy client in relation to internal investigations focusing on allegations of corruption and corporate crime, as well as on a full range of compliance matters around the world, including the United States.
Advising a purchaser on anti-bribery risk in relation to its share purchase of a group of healthcare equipment companies.
Acting on behalf of BTA Bank, Kazakhstan's largest bank, in asset recovery litigation concerning US$6 billion, the largest such case in the UK in 2013.
Advising a Fortune 200 company regarding an investigation by the DOJ and SEC into allegations that it paid bribes to secure a contract in China and similar allegations elsewhere.
Defending a pharma company on a substantial U.S. federal criminal investigation in connection with the promotion, marketing, and sale of one of its drugs.
Undertaking an internal investigation of Eletrobras, the largest electric company in Brazil, of allegations related to the Petrobras “Lava Jato” scandal.
Acting for Air Canada in the European Commission's air cargo cartel investigation and related private U.S. and UK litigation.
Investigating management responsibility for the delays to the A380, Airbus’ flagship twin-deck airliner.
We represented a private European bank regarding a Financial Services Authority (FSA) investigation into the adequacy of its anti-corruption control.
We advised a client in connection with an investigation by the UK Serious Fraud Office (SFO) into suspected overseas corruption.
We advised a multinational financial institution regarding a City of London Police investigation into alleged foreign corrupt business practices.
We advised a European paper mill producer regarding strategy and legal action in an internal fraud investigation in China.
We successfully represented one of the world's largest, most recognizable companies when they were barred from contracting with the U.S. government.
We conducted internal reviews of payments for a Fortune 500 pharmaceutical company
Our team advised one of the world's largest insurers in connection with an inquiry by the U.S. Committee on Oversight and Government Reform.